Dan Rhodes is a scientist and entrepreneur focused on precision oncology. Dan is co-founder and CEO at Strata Oncology, where he is continuing his 20+ year pursuit of understanding and applying the cancer genome and transcriptome to drive better outcomes for patients battling cancer.
Before Strata (2012-2015), Dan was Vice President of Oncology for Thermo Fisher Scientific (Life Technologies) where he oversaw the development of cancer sequencing products and pharma companion diagnostic partnerships.
From 2006-2012, Dan was co-founder and CEO of Compendia Bioscience, a University of Michigan spin-off formed to further develop and commercialize his thesis project, Oncomine, a cancer genomics data-mining platform. Over six years, Compendia grew to 20+ pharma customers and 10,000+ users, culminating in the acquisition by Life Technologies in 2012.
He has co-authored 40+ publications and is a co-inventor on 10 patents, including the discovery of gene fusions as a genetic cause of prostate cancer. He has received the Weintraub Award, a national recognition for excellence in graduate studies, the AACR Team Science Award, was a Crain’s Detroit Mergers and Acquisitions Deal of the Year Finalist, received the Michigan Venture Capital Association’s “Up and Coming Company of the Year” Award and was named Ernst & Young Entrepreneur of the Year for the Midwest region. Dan serves on the Rackham Graduate School Career Pathways Council and on the Board of Directors of Aclys Oncology.
Dan received both a Bachelor of Science in Molecular Biology and a Doctorate in Bioinformatics from The University of Michigan.
Dan and his family love summers on the lake in Michigan and snow skiing in Park City, Utah.
